ArticleCellular & molecular immunology2026
CD160
Article in Cellular & molecular immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Vitamin A-coupled MSCs- derived extracellular vesicles relieve acute liver injury by targeting hepatic stellate cells to deliver REDD1.Journal of nanobiotechnology · 2026Article
- AI-Driven Secondary Immunomodulatory Effects of Conventional Drugs on Patient-Derived Macrophages.International journal of molecular sciences · 2026Article
- Exosome-based strategies and immunotherapy for skin cancer: mechanisms, challenges, and future directions.Medical oncology (Northwood, London, England) · 2026Review
- The underexplored role of neuropilins in chronic pain pathophysiology: a review.Molecular biology reports · 2026Review
- Dysregulation of innate immune sensors and autoinflammation: insights from an NLRC4 mouse AIFEC model.Cellular & molecular immunology · 2026Article
- Decoding NF-κB: nucleocytoplasmic shuttling dynamics, synthetic modulation and post-therapeutic behavior in cancer.Molecular biology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The regenerative capacities of organs in adult mammals vary significantly. Unlike the liver, which possesses remarkable regenerative potential, the repair of cardiac injuries has long posed a critical medical challenge. Recent studies have highlighted the pivotal role of the immune microenvironment in repairing damage in these tissues, but the key cell types and their mechanisms of action remain incompletely understood. In this study, we established a model of concurrent physical trauma to the hearts and livers of adult mice, revealing that these two injured tissues drive distinct immune microenvironments. The liver primarily accumulates lymphocytes, whereas the heart recruits macrophages and neutrophils. Notably, CD160
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.